How India Exports Protein to the World

In the United States, the regulatory pathway for protein-based pharmaceuticals involves the submission of a Biologics License Application (BLA) to the FDA, as these products are typically classified as biologics. The FDA's "Purple Book" lists licensed biological products, including proteins, and provides information on biosimilarity and interchangeability. Given that the United States accounted for 4.7% of India's protein exports under HS Code 30029090, it is crucial for Indian exporters to ensure compliance with FDA regulations, including adherence to Current Good Manufacturing Practices (cGMP) and obtaining the necessary approvals for their products.

In the European Union, the European Medicines Agency (EMA) oversees the approval of protein-based pharmaceuticals through the centralized procedure, which results in a single marketing authorization valid across all EU member states. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) manages the approval process within the UK. Both agencies require compliance with EU Good Manufacturing Practice (GMP) guidelines, which are harmonized with international standards. Indian exporters targeting these markets must ensure their manufacturing facilities are GMP-certified and that their products meet the stringent quality, safety, and efficacy standards set by these regulatory bodies.

The World Health Organization (WHO) includes certain essential protein-based medicines in its Model List of Essential Medicines, which serves as a guide for countries to develop their own national lists. Inclusion in this list indicates the critical importance of these medicines in a basic health system. Additionally, the WHO Prequalification Programme assesses the quality, safety, and efficacy of medicinal products, including biologics, to ensure they meet global standards. Compliance with pharmacopoeia standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) is essential for market acceptance and regulatory approval.

In India, the Central Drugs Standard Control Organization (CDSCO) classifies protein-based pharmaceuticals under various schedules depending on their therapeutic use and potential for misuse. These classifications dictate the level of control over the sale and distribution of these medicines. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), sets ceiling prices for essential medicines to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of certain pharmaceuticals, ensuring that domestic needs are met before exportation.

The patent status of protein-based pharmaceuticals is critical in determining market exclusivity and the potential for generic competition. Patents covering the active ingredient, formulation, or method of use can prevent generic entry until expiration. The FDA's Orange Book lists patents associated with approved drug products, providing transparency for generic manufacturers. Understanding the patent landscape is essential for Indian exporters to navigate market entry strategies and avoid infringement issues.

In the past 12 months, several developments have impacted the protein-based pharmaceutical industry:

1. API Price Fluctuations: In June 2025, the NPPA reported a 5% increase in the ceiling prices of certain active pharmaceutical ingredients (APIs) used in protein-based drugs, citing rising raw material costs.

2. Regulatory Approvals: In September 2025, the CDSCO approved a new biosimilar protein product developed by an Indian manufacturer, expanding the domestic portfolio of biologics.

3. Policy Changes: In December 2025, the DGFT revised export policies, introducing streamlined procedures for obtaining NOCs for pharmaceutical exports, aiming to reduce processing times by 30%.

These developments underscore the dynamic nature of the regulatory and market environment for protein-based pharmaceuticals, necessitating continuous monitoring and adaptation by stakeholders.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of India's API requirements are sourced from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese production or export policies can lead to shortages and price volatility in the Indian pharmaceutical sector.

In response to these challenges, the Indian government has initiated measures to bolster domestic API production. In October 2024, two greenfield plants were inaugurated under the Production Linked Incentive (PLI) scheme for bulk drugs, aiming to reduce import dependence on critical APIs and KSMs. These facilities are set to manufacture essential molecules like Penicillin G, 6-Aminopenicillanic acid (6-APA), and Clavulanic Acid, which are vital components in several common antibiotics. While these efforts are commendable, the transition to self-reliance is gradual, and the industry remains susceptible to external supply chain disruptions in the interim.

Our proprietary trade data indicates a high supplier concentration in the export of "Protein" from India. The top five exporters account for 73.2% of the total export value, with PANACEA BIOTEC PHARMA LIMITED alone contributing 38.6%. Such concentration poses a significant single-source risk; any operational or financial issues faced by these key suppliers could disrupt the entire supply chain.

The PLI scheme, launched to incentivize domestic API production, has seen progress with the establishment of new manufacturing units. However, the full impact of this initiative on reducing supplier concentration and mitigating single-source risks is yet to be realized. Continuous monitoring and support are essential to ensure the diversification and resilience of the supply chain.

Recent geopolitical tensions have significantly impacted global shipping routes critical to the pharmaceutical supply chain. In February 2026, the closure of the Strait of Hormuz following military conflicts led to substantial disruptions in the movement of oil and other essential goods. This blockade affected the supply of raw materials necessary for pharmaceutical manufacturing, causing delays and increased costs. Additionally, instability in the Red Sea and the Suez Canal has forced shipping companies to reroute vessels around the Cape of Good Hope, further exacerbating delays and logistical challenges.

The U.S. Food and Drug Administration (FDA) has acknowledged these disruptions, emphasizing the need for a resilient supply chain to prevent drug shortages. The FDA actively collaborates with industry stakeholders to identify and address vulnerabilities, ensuring the continuous availability of essential medications.

• Diversify Supplier Base: Encourage the development and support of additional domestic manufacturers to reduce reliance on a limited number of suppliers.

• Enhance Domestic API Production: Accelerate the implementation and scaling of the PLI scheme to boost local production of critical APIs and KSMs.

• Strengthen Supply Chain Monitoring: Implement advanced tracking systems to monitor the supply chain in real-time, allowing for prompt responses to disruptions.

• Develop Alternative Shipping Routes: Establish and maintain alternative logistics pathways to mitigate the impact of geopolitical tensions on traditional shipping lanes.

• Foster International Collaboration: Engage in partnerships with other nations to share resources and information, enhancing global supply chain resilience.

RISK_LEVEL: HIGH